About Vir 7831:

Sotrovimab also known as VIR-7831 and GSK4182136 , sold under the brand name Xevudy, is a human neutralizing monoclonal antibody technology with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2 or COVID19. It is under development by DB16355 GlaxoSmithKline and Vir Biotechnology, Inc.

sotrovimab can be used to treat confirmed COVID-19 in adults and adolescents (aged 12 years and above and weighing at least 40 kg) who do not require supplemental oxygen therapy and who are at risk of progressing to severe COVID-19.

VIR-7831 Target:

Sotrovimab target Spike protein of SARS-CoV-2 in human and categories with the code : DB16355 in Drug Bank

VIR7831 Average Weight:

VIR7831 Average Weight is about 149 Kda .

VIR-7831 Usage :

Xevudy is given as a single treatment by infusion (drip) into a vein. The recommended dose is 500 mg given within 5 days of the patient developing symptoms of COVID-19. The medicine can only be obtained with a prescription and should be given in healthcare facilities where patients can be adequately monitored during infusion and for one hour afterwards so that they can be managed in case they develop severe allergic reactions, including anaphylaxis.

Sotrovimab function and Mechanism:

The active substance of Xevudy, sotrovimab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific structure (called an antigen). Sotrovimab has been designed to attach to the spike protein of SARS-CoV-2 (the virus that causes COVID-19). When sotrovimab attaches to the spike protein, the virus is unable to enter the body’s cells.

Vir 7831 side effect and risks:

The most common side effects (which may affect between 1 and 2 in 100 patients) are hypersensitivity (allergic) reactions and infusion-related reactions.

The most serious side effect (affecting around 5 in 10,000 patients) was anaphylaxis (severe allergic reaction).

Reference for study more:


Leave a comment

Your email address will not be published. Required fields are marked *

error: Content is protected !!
Exit mobile version